Radiosurgery and Avastin for Recurrent Malignant Gliomas

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Duke University
Study ID
NCT01017250
Status
Completed

Conditions

  • Malignant Glioma

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Stereotactic Radiosurgery (SRS) — RADIATION
    Tumor Volume \< 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
  • Bevacizumab — DRUG
    Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS

Study Details

The purpose of this study is to assess the central nervous system (CNS) toxicity in patients with recurrent malignant gliomas treated with concurrent Avastin and stereotactic radiosurgery (SRS).

Key Dates

First listed
Nov 20, 2009
Start date
Dec 31, 2009
Status verified
Jan 2014
Primary completion
Mar 31, 2011
Completion
Feb 29, 2012

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Stereotactic Radiosurgery
    Avastin and Radiosurgery

Primary Outcome Measure

Central Nervous System (CNS) Toxicity [ Time Frame: 2 months after Stereotactic Radiosurgery ]

Locations (1)

FacilityCityStateZIPSite coordinators
Duke University Medical Center, Radiation OncologyDurhamNorth Carolina27710-

Find similar trials in Durham, NC

By research site
Duke University Medical Center, Radiation Oncology· Durham, NC

Related Studies